peginterferon


Also found in: Dictionary, Thesaurus, Encyclopedia, Wikipedia.

peginterferon

/peg·in·ter·fer·on/ (peg″in″ter-fēr´on) a covalent conjugate of recombinant interferon and polyethylene glycol (PEG), with the former moiety responsible for the biological activity; conjugates of interferon alfa-2a and interferon alfa-2b are administered subcutaneously in the treatment of chronic hepatitis C infection.
References in periodicals archive ?
In group C, the score was normal (2)] were divided into the two arms randomly; (arm A; n=48) took pioglitazone 30mg/day in combination with peginterferon alpha-2a along with RBV for 48 weeks, and (arm B; n=49) were given standard of care Peg-IFN-a along with RBV for 48 weeks).
Centralized purchasing of hepatitis medicines was implemented by the MoH in 2006 (Graph 1) when monetary purchases of peginterferon 2a accounted for 97.
Sofosbuvir in combination with peginterferon alfa-2a and ribavirin for non-cirrhotic, treatment-naive patients with genotypes 1, 2, and 3 hepatitis C infection: a randomised, double-blind, phase 2 trial.
Rationale for and Clinical Development of Peginterferon Beta-1a for MS
placebo with peginterferon alfa-2a plus ribavirin for 12 weeks, followed by 36 weeks of peginterferon alfa-2a plus ribavirin (Group 3).
Victrelis which works through hepatitis C protease inhibitors, is the first of its kind in the UAE market and clinical trials have shown that when used in combination with peginterferon alfa and ribavirin in patients who were previously untreated or who had failed previous treatment therapies, Victrelis had a significantly higher chance of achieving a virological cure, than current standard therapies; a fact that could significantly reduce the overall financial burden, that patients face," he said.
The FDA approved peginterferon alfa-2a (Pegasys) and ribavirin (Copegus) for children and adolescents in this age group who have chronic hepatitis C and compensated liver disease and have not been previously treated with interferon alpha.
The FDA based its approval decision on the results of three phase III studies comparing treatment with peginterferon alfa and ribavirin (standard treatment) alone or in combination with telaprevir in about 2,250 treatment-naive and treatment-experienced adults.
Genotype 1 is treated with a 48-week course of weekly IM peginterferon and daily oral ribavirin.
Treatment with interferon/ peginterferon should be stopped if hepatic decompensation occurs (see Table 5).
The study involves 54 patients receiving telaprevir in combination with peginterferon and another treatment, ribavirin.